Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
BPC-157 remains an investigational research compound and is not approved by the U.S
FDA procedurally removed it from Category 2 in April 2026 after nominators withdrew their submissions and referred it to the Pharmacy Compounding Advisory Committee, which is scheduled to review it on July 23-24, 2026 for possible inclusion on the approved 503A bulks list
It contains bacteriostatic benzyl alcohol, which means you can re-use the same vial the second time without worrying about bacteria
Yet, the evidence base is very limited, especially in humans
Its ability to reduce pro-inflammatory cytokines and improve microcirculation suggests a powerful role in easing joint pain, muscle fatigue, and connective tissue strain
US$ 22.21
US$ 29.59
US$ 28.86
US$ 27.21
